These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36550639)

  • 41. International Survey of Trials of Convalescent Plasma to Treat COVID-19 Infection.
    Murphy M; Estcourt L; Grant-Casey J; Dzik S
    Transfus Med Rev; 2020 Jul; 34(3):151-157. PubMed ID: 32703664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Limited Correlation between SARS-CoV-2 Serologic Assays for Identification of High-Titer COVID-19 Convalescent Plasma Using FDA Thresholds.
    Larkey NE; Ewaisha R; Lasho MA; Roforth MM; Granger D; Jerde CR; Wu L; Gorsh A; Klassen SA; Senefeld JW; Joyner MJ; Baumann NA; Theel ES; Mills JR
    Microbiol Spectr; 2022 Aug; 10(4):e0115422. PubMed ID: 35862939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rapid establishment of a COVID-19 convalescent plasma program in a regional health care delivery network.
    Blackall D; Wulff S; Roettger T; Jacobs L; Lacasse A; Patri M; Zinser P; Pherez F; Jamkhana Z; Frey SE; Smith L; Goel R; Katz L
    Transfusion; 2020 Oct; 60(10):2203-2209. PubMed ID: 32748963
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.
    Wendel S; Land K; Devine DV; Daly J; Bazin R; Tiberghien P; Lee CK; Arora S; Patidar GK; Khillan K; Smid WM; Vrielink H; Oreh A; Al-Riyami AZ; Hindawi S; Vermeulen M; Louw V; Burnouf T; Bloch EM; Goel R; Townsend M; So-Osman C
    Vox Sang; 2021 Sep; 116(8):872-879. PubMed ID: 33772791
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations.
    Del Fante C; Franchini M; Baldanti F; Percivalle E; Glingani C; Marano G; Mengoli C; Mortellaro C; Viarengo G; Perotti C; Liumbruno GM
    Transfusion; 2021 Mar; 61(3):830-838. PubMed ID: 33231325
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.
    Russell WA; Grebe E; Custer B
    Transfusion; 2021 May; 61(5):1370-1376. PubMed ID: 33590906
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blood Endothelial-Cell Extracellular Vesicles as Potential Biomarkers for the Selection of Plasma in COVID-19 Convalescent Plasma Therapy.
    Amri N; Tessier N; Bégin R; Vachon L; Bégin P; Bazin R; Loubaki L; Martel C
    Cells; 2022 Oct; 11(19):. PubMed ID: 36231083
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of responses of the health care workers recovered from COVID-19 on convalescent plasma donation by apheresis: A single-center survey study.
    Sahu A; Prakash S; Singh AK; Mukherjee S
    J Clin Apher; 2022 Jun; 37(3):273-280. PubMed ID: 35119768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Validation of a SARS-CoV-2 RNA RT-PCR assay for high-throughput testing in blood of COVID-19 convalescent plasma donors and patients.
    Strasser EF; Steininger PA; Korn K; Achenbach S; Tenbusch M; Cunningham S; Zimmermann R; Überla K; Hackstein H
    Transfusion; 2021 Feb; 61(2):368-374. PubMed ID: 33125162
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should timing be considered before abandoning convalescent plasma in covid-19? Results from the Turkish experience.
    Ateş İ; Erden A; Güven SC; Gürler EK; Çağlayan A; Güçbey Ö; Apaydın H; Şahiner ES; Küçük H; Varan Ö; Omma A; Küçükşahin O
    Transfus Apher Sci; 2021 Dec; 60(6):103238. PubMed ID: 34412949
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Offering new and returned donors the option to give plasma: implications for donor retention and donor adverse events.
    Thijsen A; Davison TE; Speedy J; Hoad V; Masser B
    Vox Sang; 2021 Mar; 116(3):273-280. PubMed ID: 32702163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors.
    Bansal N; Raturi M; Bansal Y
    Transfus Clin Biol; 2021 Aug; 28(3):308-309. PubMed ID: 33971319
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients.
    Franchini M; Focosi D; Percivalle E; Beccaria M; Garuti M; Arar O; Pecoriello A; Spreafico F; Greco G; Bertacco S; Ghirardini M; Santini T; Schiavulli M; Stefania M; Gagliardo T; Sammartino JC; Ferrari A; Zani M; Ballotari A; Glingani C; Baldanti F
    Viruses; 2022 Jun; 14(7):. PubMed ID: 35891421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study.
    Alsharidah S; Ayed M; Ameen RM; Alhuraish F; Rouheldeen NA; Alshammari FR; Embaireeg A; Almelahi M; Adel M; Dawoud ME; Aljasmi MA; Alshammari N; Alsaeedi A; Al-Adsani W; Arian H; Awad H; Alenezi HA; Alzafiri A; Gouda EF; Almehanna M; Alqahtani S; Alshammari A; Askar MZ
    Int J Infect Dis; 2021 Feb; 103():439-446. PubMed ID: 33285283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Establishing the First COVID-19 Convalescent Plasma Biobank in Jordan.
    Souan L; Sughayer MA; Abu Alhowr MM
    Biopreserv Biobank; 2022 Oct; 20(5):423-428. PubMed ID: 35904406
    [No Abstract]   [Full Text] [Related]  

  • 58. The impact of COVID-19 on blood safety and availability in the Islamic Republic of Iran.
    Divkolaye N; Arabkhazaeli A; Hajibeigi B; Eshghi P
    East Mediterr Health J; 2022 Nov; 28(11):823-828. PubMed ID: 36515446
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?
    Wendel S; Fachini R; Fontão-Wendel RCL; Mello R; Velasquez CV; Machado RRG; Brito MA; Amaral M; Soares CP; Achkar R; Scuracchio P; Miyaji SC; Erdens MS; Durigon EL
    Transfusion; 2021 Dec; 61(12):3455-3467. PubMed ID: 34674284
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Associations Between Symptoms, Donor Characteristics and IgG Antibody Response in 2082 COVID-19 Convalescent Plasma Donors.
    Vinkenoog M; Steenhuis M; Brinke AT; van Hasselt JGC; Janssen MP; van Leeuwen M; Swaneveld FH; Vrielink H; van de Watering L; Quee F; van den Hurk K; Rispens T; Hogema B; van der Schoot CE
    Front Immunol; 2022; 13():821721. PubMed ID: 35296077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.